Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has shared an announcement.
Mayne Pharma reported a mixed unaudited trading update for the first five months of FY26, with group net revenue down 5.5% to $165 million and underlying EBITDA roughly halved to $11.5 million amid higher marketing spend, FDA post-approval study costs and pricing pressure in parts of its dermatology portfolio. While total direct contribution slipped 7.3% to $49.7 million, the company highlighted strong prescription and volume growth across its women’s health franchise, improved gross margins in dermatology driven by TWYNEO and EPSOLAY, and stronger international gross margins, underpinned by Australia’s PBS listing for NEXTSTELLIS, expected US regulatory tailwinds for BIJUVA and IMVEXXY, and ongoing investment in sales, marketing and domestic manufacturing as the board reviews strategic options to maximise long-term shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an Australian specialty pharmaceutical company focused on women’s health, dermatology and international branded and generic medicines. Its key products include contraceptive and menopause treatments such as NEXTSTELLIS, BIJUVA, IMVEXXY and ANNOVERA, alongside recently acquired dermatology brands TWYNEO and EPSOLAY, supported by manufacturing operations including an expanded Salisbury facility and a growing direct-to-patient channel in Australia.
YTD Price Performance: -37.22%
Average Trading Volume: 556,881
Technical Sentiment Signal: Sell
Current Market Cap: A$253.5M
For an in-depth examination of MYX stock, go to TipRanks’ Overview page.